US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Bristol-Myers Squibb Company

BMYNYSE

76.14

USD
-1.45
(-1.87%)
After Hours Market
27.48P/E
9Forward P/E
1.06P/E to S&P500
162.107BMarket CAP
2.65%Div Yield

Bristol-Myers Squibb Company

NYSE:BMY

RECENT
PRICE

76.14

P/E
RATIO

27.48

(PEG:0.15)

P/E RATIO
RELATIVE
TO S&P

1.06

DIV
YLD

3.07%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

- - Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

9.14

0.81

0.66

1.12

9.82

1.10

1.17

1.12

10.42

2.65

1.40

1.24

9.53

5.38

1.69

1.26

11.37

1.81

2.37

1.29

12.50

2.18

2.63

1.33

10.55

1.17

3.83

1.37

9.97

1.56

1.83

1.40

9.58

1.21

1.58

1.45

9.93

0.94

0.61

1.49

11.63

2.67

0.98

1.52

12.63

0.61

2.57

1.57

13.82

3.01

3.06

1.60

15.33

2.02

4.24

1.57

18.83

(3.99)

5.89

1.80

20.54

3.11

6.75

1.95

21.22

2.83

6.84

2.02

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.40

5.10

0.43

5.36

0.48

6.19

0.37

7.52

0.25

9.17

0.22

9.39

0.33

8.16

0.33

9.22

0.32

8.96

0.49

8.56

0.73

9.68

0.64

7.14

0.58

8.59

0.49

30.26

0.33

16.75

0.43

15.95

0.48

16.00

CAPEX per share

Book Value per share

1,960

1,970

1,977

1,974

1,713

1,700

1,670

1,644

1,657

1,667

1,671

1,645

1,633

1,705

2,258

2,258

2,213

Comm.Shares outs.(m)

29.8

1.6

4.7%

26.1

1.5

3.9%

8.1

0.4

5.8%

4.0

0.1

5.8%

14.1

0.7

5.0%

13.2

0.8

4.6%

28.5

1.9

4.1%

28.2

1.7

3.2%

43.3

2.4

2.8%

68.3

3.4

2.3%

23.8

1.1

2.4%

93.6

4.0

2.7%

19.1

0.8

2.8%

24.9

1.0

3.1%

(15.1)

(0.4)

3.0%

20.2

0.7

3.1%

27.5

1.1

3.1%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$71,389 m.

Total assets
$103,034 m.

Long-term debt
$37,450 m.

Cash and equiv.
$12,369 m.

Goodwill $20,500 m.

Retained earnings $23,948 m.

Common stock 2,202 m. shares

Market Capitalisation
$165,194 m. (as of 27/5/22)

21,244

31.3%

17,621

22.3%

16,385

17.9%

15,879

10.8%

16,560

10.4%

19,427

23.4%

20,776

16.6%

22,561

22.7%

26,145

22.6%

42,518

5.1%

46,385

15.9%

46,960

22.7%

Revenue (m)

Operating margin

801

3,709

681

1,960

763

2,563

467

2,004

376

1,565

382

4,457

789

1,007

637

4,920

1,746

3,439

10,380

(9,015)

10,686

7,014

10,602

6,271

Depreciation (m)

Net profit (m)

24.7%

17.5%

(6.9)%

11.1%

10.8%

15.6%

14.8%

12.6%

21.5%

9.5%

23.8%

22.9%

81.0%

4.8%

17.1%

21.8%

30.5%

13.2%

(30.9)%

(21.2)%

13.4%

15.1%

14.0%

13.3%

Income tax rate

Net profit margin

7,538

5,376

15,956

1,242

6,568

13,623

6,476

7,981

15,154

6,147

7,242

14,852

2,398

6,550

14,266

4,863

5,716

16,177

5,291

6,975

11,741

6,506

5,646

14,031

11,050

43,387

51,598

11,112

49,169

37,822

11,394

39,605

36,006

7,300

37,450

31,580

Working capital (m)

Long-term debt (m)

Equity (m)

16.6%

16.9%

23.2%

7.7%

5.5%

14.4%

10.5%

8.0%

16.9%

8.7%

7.6%

13.5%

7.3%

6.9%

11.0%

18.6%

18.0%

27.6%

4.3%

16.0%

8.6%

20.9%

17.6%

35.1%

3.5%

4.3%

6.7%

(7.2)%

(4.6)%

(23.8)%

8.0%

7.4%

19.5%

8.5%

7.7%

19.9%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

15,393

17,593

17,026

Receivables

7,685

8,501

9,369

Inventory

4,293

2,074

2,095

Other

1,983

3,167

4,832

Current assets

29,354

30,192

33,262

Acc. Payable

2,445

2,713

2,949

Debt due

3,479

2,504

4,948

Other

12,380

13,863

13,971

Current liab.

18,304

19,080

21,868

39.2%

64.3%

(16.6)%

66.1%

9.9%

72.4%

(19.7)%

80.5%

(58.3)%

218.5%

42.9%

158.8%

(155.9)%

119.6%

46.9%

58.8%

22.1%

138.0%

145.2%

- -

37.3%

70.1%

28.7%

92.4%

Plowback ratio

Div.&Repurch. to FCF

Bristol-Myers Squibb Company (US) started trading on July 5, 1929 (cik: 0000014272), operates in the Healthcare sector (Drug Manufacturers—General industry), has 32,200 full-time employees, and is led by Dr. Giovanni Caforio. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

24.05%

12.74%

Cash flow

40.41%

28.23%

Earnings

-45.37%

-9.67%

Dividends

15.98%

8.45%

Book value

63.94%

27.45%

Insider trading

Type

Shares

Date

Greenlees Sharon

Award

4,134

05/02/22

Greenlees Sharon

Award

2,756

05/02/22

Greenlees Sharon

Award

1,312

05/02/22

Shanahan Karin

Award

13,225

04/01/22

Mily Elizabeth

Exempt

2,685

04/01/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

10,781

10,129

10,540

11,068

42,518

2021

11,073

11,703

11,624

11,985

46,385

2022

11,648

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

(0.34)

(0.04)

0.83

(4.44)

-3.99

2021

0.90

0.47

0.68

1.06

3.11

2022

0.58

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

0.45

0.45

0.45

0.45

1.80

2021

0.49

0.49

0.48

0.49

1.95

2022

0.54

- -

- -

- -

- -

04/29/2022

FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease

The Wall Street Journal - Read more...

10/16/2020

NIH to Study Three Drugs in Treatment of Covid Patients

The Wall Street Journal - Read more...

10/06/2020

Bristol-Myers Squibb Cuts Its Cancer Risk

The Wall Street Journal - Read more...

10/05/2020

Bristol to Pay $13.1 Billion for Heart-Drug Maker MyoKardia

The Wall Street Journal - Read more...